If you keep up with hair loss news, you’ve almost certainly seen the headlines: a new breakthrough drug is regrowing 539% more hair. This news has exploded across social media and news outlets, with many hailing it as the long-awaited cure for baldness. The company behind the drug, known as Clascoterone or Breezula, even saw its stock price surge by 40%. On the surface, it sounds like the miracle we’ve all been waiting for. After all, if the current gold standard, Finasteride, increases hair counts by about 9%, a 539% increase must be world-changing, right? You might be tempted to throw out your current treatments and wait for this game-changer to hit the market.
But not so fast. As with many things that sound too good to be true, there’s a major catch. That incredible 539% figure is deeply misleading, and the company’s own data, both new and old, tells a very different story. In this article, we’re going to pull back the curtain on Clascoterone. We’ll dissect that headline-grabbing number, look at the clinical data the drug makers might not want you to see, and give you a realistic picture of what this new treatment can—and can’t—do. My goal is to help you navigate the often-confusing world of hair loss treatments so you can make the best decisions for your hair and your health. (Based on the insights of Rob English)
Key Takeaways
- The widely reported “539% increase in hair” from Clascoterone is not an absolute increase. It’s a misleading statistic comparing its tiny effect to the even tinier effect of a placebo.
- Past clinical trials showed that Clascoterone was less effective than Minoxidil, a common over-the-counter hair loss treatment.
- The before-and-after photos released by the company are underwhelming and likely represent the absolute best-case results from a 1,500-person study.
- Patient self-assessments of hair growth were weak, with one of the two major studies failing to show a statistically significant improvement.
- You should not delay or stop using proven hair loss treatments like Finasteride or Minoxidil while waiting for Clascoterone to become available.
1. What Is Clascoterone? The Basics Explained
First, let’s understand what this drug actually is. Clascoterone is a topical medication, meaning you apply it directly to your scalp. It works as an androgen receptor antagonist. Think of your hair follicle cells as having little landing pads (receptors) for male hormones (androgens) like DHT (dihydrotestosterone). In androgenic alopecia (male and female pattern hair loss), DHT binds to these receptors and triggers the process of hair follicle miniaturization, which leads to thinning and balding.
Clascoterone works by blocking these landing pads. If DHT can’t attach to the cell, it can’t send the signal to shrink the hair follicle. The big appeal is that it’s designed to work locally on the scalp with minimal absorption into the rest of your body, which could mean fewer systemic side effects. In fact, a 1% version of this drug is already FDA-approved to treat acne in teenagers, suggesting a strong safety profile.
2. The 539% Claim: Why It’s Not What You Think
This is the most important part to understand. The press release didn’t say Clascoterone caused a 539% increase in hair from your baseline. It said the increase was 539% relative to the placebo. This sounds like a minor difference in wording, but it’s a massive distinction.
Let me show you how this statistical trick works. Imagine a study where the placebo group (using a fake treatment) starts with 100 hairs and ends with 101 hairs after six months. That’s an increase of just one hair. Now, imagine the Clascoterone group starts with 100 hairs and ends with 106 hairs. That’s an increase of six hairs.
If you compare the drug’s effect (+6 hairs) to the placebo’s effect (+1 hair), you can say the drug was 600% more effective than the placebo. This is how they get to a number like 539%. The actual, absolute change could be cosmetically insignificant, but the relative percentage sounds incredible. The company deliberately left the absolute hair count changes out of its press release, which is a major red flag. For all we know, the real change could be a handful of hairs, not the luscious mane the headlines imply.
3. A Look Back: Clascoterone vs. Minoxidil
This isn’t the first time Clascoterone has been studied for hair loss. Over seven years ago, before being acquired by the current company, Clascoterone was tested against Minoxidil (Rogaine), one of the two FDA-approved mainstays for hair loss.
In one study with men, 5% Clascoterone did beat the placebo, which is good. However, 5% Minoxidil beat Clascoterone. The absolute increase in hair count for Clascoterone was about 12 hairs—a far cry from 539%. In another study on women, Clascoterone didn’t even beat the placebo, while Minoxidil did. These older studies begin to paint a picture of a treatment that, while it may have some effect, is likely not as powerful as the treatments we already have.
4. The Pecking Order: Where Clascoterone Ranks Among Hair Loss Treatments
Based on the available data, we can start to build a hierarchy of effectiveness for topical treatments. We know from multiple studies that Finasteride is generally more effective long-term than Minoxidil. We also know that Minoxidil works faster than Finasteride but its effects can wane after the first year. And from the older trials, we know that Minoxidil appears to be more effective than Clascoterone.
So, the hierarchy looks something like this:
Finasteride > Minoxidil > Clascoterone
While Clascoterone could be a useful addition, especially for those who can’t tolerate other treatments, it’s highly unlikely to outperform the current gold standards. It’s a smaller punch, not a knockout blow to baldness.
5. A Picture Is Worth a Thousand Words… Or Is It?
To generate excitement, the company released before-and-after photos from two participants in their 1,500-person trial. You have to assume these are the best, most impressive results they could find. And frankly, they’re underwhelming.
The photos show what might be very slight improvements in thickness or a minor filling-in of the crown. They are nowhere near the kind of regrowth people see in great responses to Finasteride or Minoxidil. When a company shows you its best results and your reaction is, “I guess I see a small difference?” it tells you a lot. The average result is going to be even less noticeable. To add to this, the patient self-assessment data was weak. In one of the two studies, patients themselves weren’t even sure if the treatment was working in a statistically significant way.
6. How to “Cheat” a Hair Loss Study (And Why You Should Be Skeptical)
As a consumer, it’s helpful to know how study results can be manipulated to look better than they are. One way is to abuse the “law of small numbers.” If you measure hair growth in a nearly bald spot that only has 5 hairs, and the treatment grows just 2 more hairs, that’s a 40% increase! If you do the same on a person with 100 hairs, growing 2 more hairs is only a 2% increase. By cherry-picking participants with advanced hair loss or measuring in the baldest areas, researchers can generate huge percentage gains from tiny, cosmetically meaningless results.
Another trick is to change the definition of what counts as a “real” hair. Studies can either count only thick, terminal hairs or lump them in with vellus hairs (the fine, invisible “peach fuzz”). Including vellus hairs can dramatically inflate hair count numbers without adding any visible density. While the Clascoterone trial claims to measure “non-vellus” hairs, they don’t define their threshold, leaving a loophole for questionable data.
7. Your Next Move: Should You Wait for This New Drug?
The final verdict is clear: you should absolutely temper your expectations for Clascoterone. While it’s great to have another potential tool in the toolbox, it is not the miracle cure portrayed in the headlines. The evidence strongly suggests it is less effective than the treatments that are already on the market, affordable, and accessible right now.
Delaying treatment for hair loss is a big mistake. There is a window of reversibility, and the longer you wait, the harder it is to regain lost ground. Waiting months or years for a new drug that will likely be less effective than current options means you’re losing hair that you might never get back.
Conclusion
I hope Clascoterone proves to be a safe and useful option for some people. More choices are always a good thing. However, the marketing around its latest trial results has been irresponsible and misleading. It preys on the hopes of people desperate for a solution. For now, your best bet is to stick with what we know works. Treatments like Finasteride and Minoxidil have decades of data and proven track records of success. Don’t let the hype around a new product distract you from taking effective action today. Your future hair will thank you for it.
Source: Rob English